Journal
ALZHEIMERS & DEMENTIA
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1002/alz.12798
Keywords
consensus; Delphi procedure; etiological diagnosis; imaging; major neurocognitive disorder; MCI; mild dementia; biomarker; neurocognitive disorders
Categories
Funding
- F. Hoffmann-La Roche Ltd.
- Biogen International GmbH
- Eisai Europe Limited
- Life Molecular Imaging GmbH
- OM Pharma Suisse SA
- Italian Ministry of Health
- Astra-Zeneca
- H. Lundbeck
- Novartis Pharmaceuticals
- Evonik
- Roche Diagnostics
- GE Health
- National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London
- AriSLA (Fondazione Italiana di Ricerca per la SLA)
- European Research Council
- HORIZON 2020 (H2020-MSCA-ITN-2016) [721281]
- Instituto de Salud Carlos III (CIBERNED)
- EU/EFPIA Innovative Medicines Initiative Joint Undertaking, ADAPTED [115975]
- EXIT project, EU Euronanomed3 Program JCT2017 [AC17/00100]
- PREADAPT project. Joint Program for Neurodegenerative Diseases (JPND) [AC19/00097]
- Accion Estrategica en Salud, integrated in the Spanish National RCDCI Plan
- Instituto de Salud Carlos III (ISCIII) -Subdireccion General de Evaluacion
- Fondo Europeo de Desarrollo Regional (FEDER -Una manera de Hacer Europa)
- Fundacion bancaria La Caixa
- Grifols SA (GR@ACEproject)
- A.P.R.A. -Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Geneve
- Fondation Segre, Geneve
- Ivan Pictet, Geneve
- Fondazione Agusta, Lugano
- Fondation Chmielewski, Geneve
- Fondation Minkoff, Geneve
- Race Against Dementia Foundation, London, UK
- ROCHE Pharmaceuticals
- OM Pharma
- EISAI Pharmaceuticals
- Biogen Pharmaceuticals
- Novo Nordisk
- H2020, Innovative Medicines Initiative (IMI), IMI2
- Swiss National Science Foundation
- VELUX Foundation
- Hummingbird GmbH
- Noselab GmbH
- Swiss National Science Foundation [185028, 188355, 169876]
- Aetas Foundation
- Schmidheiny Foundation
- Siemens Healthineers
- GE Healthcare
- Roche
- Merck
- Cerveau Technologies
- Life Molecular Imaging
- Innovative Medicines Initiatives
- EU Health and Research Programmes
- ADx
- AVID Radiopharmaceuticals
- Biogen
- Eli Lilly
- Eisai
- Fujirebio
- GEHealthcare
- Pfizer
- Parexel
- Reta Lila Weston Trust
- NIHR UCLH
- Wellcome Trust
- Muscular Dystrophy Association USA
- BMBF -FTLD consortium
- Moodmarker
- ALS association
- EU -MIRIADE
- AC Immune
- FUJI-film/Toyama
- IONIS
- UCB
- Vivoryon
- ZonMW
- NWO
- EU-FP7
- EUJPND
- Alzheimer Nederland
- Hersenstichting CardioVascular Onderzoek Nederland
- Health similar toHolland, Topsector Life Sciences Health
- Stichting Dioraphte
- Gieskes-Strijbis fonds
- Sichting Equilibrio
- Edwin Bouw fonds
- Pasman stichting
- Stichting Alzheimer & Neuropsychiatrie Foundation
- Philips
- BiogenMAInc
- Novartis-NL
- Life-MI
- AVID
- Roche BV
- Fujifilm
- Combinostics
- Pasman chair
- ABOARD from ZonMW [73305095007]
- Health similar to Holland, Topsector Life Sciences & Health (PPP-allowance) [LSHM20106]
- Universite de Geneve
- [PI13/02434]
- [PI16/01861 BA19/00020]
- [PI19/01301]
Ask authors/readers for more resources
This study developed a pan-European workflow for the etiological diagnosis of neurocognitive disorders in middle-old age based on biomarkers. The workflow was developed through a Delphi consensus method and a systematic literature review, aiming to provide guidance for the rational use of biomarkers in clinical practice.
Introduction Etiological diagnosis of neurocognitive disorders of middle-old age relies on biomarkers, although evidence for their rational use is incomplete. A European task force is defining a diagnostic workflow where expert experience fills evidence gaps for biomarker validity and prioritization. We report methodology and preliminary results. Methods Using a Delphi consensus method supported by a systematic literature review, 22 delegates from 11 relevant scientific societies defined workflow assumptions. Results We extracted diagnostic accuracy figures from literature on the use of biomarkers in the diagnosis of main forms of neurocognitive disorders. Supported by this evidence, panelists defined clinical setting (specialist outpatient service), application stage (MCI-mild dementia), and detailed pre-assessment screening (clinical-neuropsychological evaluations, brain imaging, and blood tests). Discussion The Delphi consensus on these assumptions set the stage for the development of the first pan-European workflow for biomarkers' use in the etiological diagnosis of middle-old age neurocognitive disorders at MCI-mild dementia stages. Highlights Rational use of biomarkers in neurocognitive disorders lacks consensus in Europe. A consensus of experts will define a workflow for the rational use of biomarkers. The diagnostic workflow will be patient-centered and based on clinical presentation. The workflow will be updated as new evidence accrues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available